Vericel Corporation

Vericel Corporation manufactures and markets advanced cell therapy products for sports medicine and severe burn care in the United States. The company's primary product portfolio includes MACI (matrix-induced autologous chondrocyte implantation), an autologous cell therapy for repair of symptomatic knee cartilage defects using patient's own cells cultured on a porcine collagen membrane. MACI is now available with arthroscopic delivery (MACI Arthro) following FDA approval in August 2024, enabling minimally invasive treatment of full-thickness cartilage defects up to 4 cm². Epicel is Vericel's advanced cell therapy for severe burn care, utilizing autologous keratinocytes. The company also holds an exclusive license for North American commercial rights to NexoBrid® (anacaulase-bcdb), a biological orphan product approved for enzymatic eschar removal in deep partial-thickness and full-thickness thermal burns, with pediatric indication approved by the FDA in August 2024. All products are FDA-approved biologics. Vericel serves orthopedic surgeons, burn care specialists, and hospital systems across the United States. The company operates manufacturing and distribution capabilities supporting personalized cell therapy delivery.